AbCellera
Update in progressABCL (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
AbCellera Biologics discovers and develops antibody-based medicines for unmet medical needs in the United States. Its lead candidate, ABCL635, is a non-hormonal therapy in Phase 2 for moderate-to-severe vasomotor symptoms. ABCL575 is a fully human, half-life–extended monoclonal antibody in Phase 1 for T-cell–mediated autoimmune conditions such as atopic dermatitis. The company collaborates with Eli Lilly, AbbVie, Biogen, Viking Global and ArrowMark. Founded 2012, based in Vancouver.
Company score
- Sentiment
- 0.35
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.15
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!